Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraphene Nanochem Regulatory News (GRPH)

  • There is currently no data for GRPH

Notice of EGM

20 May 2008 16:35

RNS Number : 9101U
Biofutures International plc
20 May 2008
Β 

ο»Ώ

For Immediate Release 20 May 2008Β 

Biofutures International plc

("Biofutures" orΒ theΒ "Company")

Notice ofΒ Extraordinary General Meeting ("EGM")

Biofutures today announces that it has sent a circular to its shareholdersΒ ("Shareholders")Β containing a notice of anΒ EGMΒ to be held atΒ the offices ofΒ Stephenson Harwood, One St Paul's Churchyard, London EC4M 8SHΒ at 11.00Β a.m. onΒ 6 JuneΒ 2008.

At this EGM, the boardΒ of Biofutures ("Board" or "Directors")Β proposeΒ to seek Shareholder approval toΒ two ordinary resolutions.

Β 

1. To approveΒ the cancellation of the agreement made by the Directors in the documentΒ sent toΒ 

Shareholders seeking,Β inter alia, the approval for the acquisition of ZurexΒ Corporation Sdn. Bhd

("Zurex"), dated 30 October 2006, to the effect that if sufficient bank facilities were not entered into,

and other forms of financing could not be found, the Company may decide not to proceed further with

the construction of the palm oil biodiesel plant ("Zurex Project") and instead seek, subject to obtaining

POIC's permission, to sell its rights to the development of the palm oil biodiesel plant to a third party

and to return its remaining cash resources to Shareholders or obtain Shareholder consent to make an

alternative investmentΒ ("Restrictive Agreement").

The Restrictive Agreement prevents the Directors from making other investments, in the event that the Directors decide not to proceed with the construction of the Zurex Project, without,Β inter alia, first seeking Shareholders' approval to re-invest Shareholders' funds as opposed to winding up the Company and returning any funds from the termination of the Zurex Project to Shareholders. Without this ability to make other investments (which includesΒ the ability to invest in the Refinery Project, detailed below)Β the Directors are prevented from expanding the Company's business unless the Zurex Project is first terminated, which the Directors do not believe to be in the best interests of Shareholders at this time.Β 

2. To approveΒ theΒ investing strategy,Β which is

"to continue to review the Zurex Project includingΒ potentiallyΒ re-engineering the project into the Refinery Project which, through the addition of a plant module could be expanded into a palm oil biodiesel plant should the production of palm oil biodiesel become economically feasible and / or to invest in or acquire projects, assets, partnerships, joint ventures, businesses or companies (public or private) in Europe, Asia and the Middle East in the energy and utility sectors and their related infrastructures. Acquisitions and investments may be funded with cash, equity, debt or any mixture of the aforementionedΒ ("Investing Strategy")"Β 

and therefore the reclassificationΒ of BiofuturesΒ from a trading company to an Investing Company, as defined by the AIM Rules for Companies.

Zurex, a wholly owned subsidiary of Biofutures which acts as a holding company, was incorporated in Malaysia to establish a 200,000 tonnes per annum palm oil biodiesel plant at POIC Lahad Datu, Sabah, Malaysia. Zurex's strategy was to produce palm oil biodiesel from the feedstock of refined and crude palm oil inΒ MalaysiaΒ and to sell the palm oil biodiesel produced.Β 

Having completed the review of the Zurex Project the Directors believe that the Zurex Project, as currently defined, is no longer economically viable. However, having consideredΒ the global trendΒ which showsΒ an increased demand forΒ palm oil and the resultant rise in prices, theΒ DirectorsΒ consider it a viable option (as part of the re-engineering exercise) to consider the refining of palm oil (through the Refinery Project) while retaining the flexibility to consider the production of palm oil biodiesel should economic circumstances permit in the future.

The refining of palm oil requires similar technologies to that which would have been utilised in the pre-treatment stage of the palm oil biodiesel plant under the Zurex Project, and thus the pre-treatment plant can be redesigned to become a palm oil refinery. If commissioned, the plant will initially be built as a palm oil refining plant and if a palm oil biodiesel plant becomes economically feasible, a trans-esterification moduleΒ and associated ancillary equipmentΒ could be added to the Refinery Project to enable the production of palm oil biodiesel.Β 

Once all necessary approvals are obtained and the Directors are satisfied on the feasibility of the Refinery Project theyΒ intend to utilise available funds to commission the Refinery Project and to maximize the use of existing assets that have been acquired and paid for by the Company without raising additional funds for capital expenditure. Working capital facilities will however be required to finance the Refinery Project in the initial period of its operations. The Directors believe that by using the 14 acres of land and the equipment that has been acquired to date, the value in the initial investment cost can be optimised and lossesΒ kept to the minimum.

For the six months ended 30 June 2007 losses attributable to the Zurex Project were Β£0.11 million and the total asset value relating to the Zurex Project was Β£20.73 million. For the same period the GroupΒ (Biofutures and Zurex)Β made losses of Β£0.45 million and had total assets of Β£29.41 million, of which Β£8.65 million was cash. As at 30 April 2008 available cash was Β£8.17 million.

In order to be in a position to increase Shareholder value the Board are seeking Shareholders' approval toΒ consider the refining of palm oil while retaining the flexibility to produce biodioeselΒ should economic circumstances permit. In addition, the Board would like Shareholders' approvalΒ to invest in other businesses and investments when opportunities arise in line with their proposed InvestingΒ Strategy.

Although the Directors believe that Biofutures could exist in its current form for the foreseeable future, by maximising interest income and minimising expenditure, without either making an investment or returning funds to Shareholders,Β the DirectorsΒ would like to persue an active strategy of investment. The DirectorsΒ intend that Biofutures makesΒ at least one investment in theΒ next twelve months, which could be anΒ investment into the Refinery Project.

The members of the Board and its management team are made up of experienced individuals with diverse backgrounds covering legal, financial, engineering and energy related chemical industries with experience in corporate transactions over a variety of sectors. The Directors will be guided by their experiences in their respective fieldsΒ of expertise and management skills in implementing the Investing Strategy. Investments and acquisitions will be subject to the relevant legal and financial due diligence being first made, and where necessary, the Company will appoint suitably qualified consultants and market researchers to advise the Directors on the feasibility and risks associated with any potential acquisition or investment.Β 

The Investing Strategy, if approved, will guide the future direction of Biofutures which at present is unclear to Shareholders due to the uncertainty regarding the viability and direction of the Zurex Project. If Shareholders' approval is obtained in relation to theΒ Investing Strategy, Biofutures will be reclassified from a trading company to an Investing Company, as defined by the AIM Rules for Companies, with Zurex being one of Biofutures' existing investments. This reclassification will be viewed as a fundamental change of business and as an Investing Company Biofutures will therefore have to make an acquisition or acquisitions which constitute a reverse takeover under the AIM Rules for Companies or otherwise implement itsΒ Investing StrategyΒ to the satisfaction of the London StockΒ ExchangeΒ within twelve months of having received the consent of Shareholders at the EGM. If this does not occur, trading in the Company's Ordinary Shares will be suspended.

For further information please contact:

Julie Pomeroy, Finance Director

Biofutures International Plc 0117 920 0092

Emily Morgan

Blomfield Corporate FinanceΒ  Β 01275Β 871Β 717

Paul Vann

Winningtons Financial PR 0117 920 0092

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NOEFKKKNPBKDQPB
Date   Source Headline
16th Mar 20187:00 amRNSAcquisition Update and AIM Cancellation
16th Feb 20187:00 amRNSConfirmation of Resignation of Nomad and Broker
31st Jan 20181:47 pmRNSNotice of Resignation of Nomad and Broker
17th Jan 20189:24 amRNSResignation of Director
8th Jan 20182:50 pmRNSProposed Acquisition Update
30th Nov 20177:30 amRNSSuspension - Graphene Nanochem Plc
30th Nov 20177:00 amRNSProposed Acquisition and Suspension of Trading
12th Oct 20174:40 pmRNSSecond Price Monitoring Extn
12th Oct 20174:35 pmRNSPrice Monitoring Extension
11th Oct 20174:40 pmRNSSecond Price Monitoring Extn
11th Oct 20174:35 pmRNSPrice Monitoring Extension
29th Sep 201711:30 amRNSInterim Results
13th Sep 20179:31 amRNSHolding(s) in Company
13th Sep 20179:27 amRNSHolding(s) in Company
11th Sep 201712:07 pmRNSSecond Price Monitoring Extn
11th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 201711:45 amRNSConversion of Loan Notes and Issue of Equity
4th Sep 201710:15 amRNSConversion of loan note and issue of equity
2nd Aug 20171:20 pmRNSConversion of loan note and issue of equity
26th Jul 201711:30 amRNSResult of Annual General Meeting
4th Jul 20179:59 amRNSConversion of loan note and issue of equity
30th Jun 20177:03 amRNSPreliminary Results
27th Jun 20174:35 pmRNSPrice Monitoring Extension
23rd Jun 20174:35 pmRNSPrice Monitoring Extension
13th Jun 20177:00 amRNSPolymer Division Paid Pilot
22nd May 201712:54 pmRNSPlatDrill Deployment In Myanmar
15th May 201712:35 pmRNSIssuance of Tranche 2 Loan Notes
12th Apr 20172:47 pmRNSConversion of loan note and issue of equity
3rd Apr 201711:47 amRNSConversion of Loan Note and Issue of Equity
31st Mar 20179:05 amRNSUpdate on Debt Rationalisation
8th Mar 201712:00 pmRNSConversion of loan note and issue of equity
3rd Mar 20177:00 amRNSCommercial deployment in Turkmenistan
20th Feb 20174:40 pmRNSSecond Price Monitoring Extn
20th Feb 20174:35 pmRNSPrice Monitoring Extension
3rd Feb 20177:00 amRNSConversion of loan note and issue of equity
29th Dec 20164:19 pmRNSFurther information on 2015 report and accounts
28th Dec 20167:00 amRNSContract Win
23rd Dec 201612:35 pmRNSPrice Monitoring Extension
23rd Dec 20168:45 amRNSRestoration - Graphene NanoChem PLC
23rd Dec 20168:15 amRNSIssuance of Loan Notes and Resumption of Trading
6th Dec 20162:44 pmRNSResult of AGM
14th Nov 20165:04 pmRNSInterim Results
14th Nov 20165:01 pmRNSProposed Share Capital Reorganisation
14th Nov 20165:00 pmRNSPreliminary Results
31st Oct 20164:35 pmRNSUpdate on pending 2015 Annual Results
30th Sep 20163:20 pmRNSUpdate on 2015 Annual Results & 2016 Interims
1st Sep 20161:21 pmRNSUpdate on pending 2015 Annual Results
29th Jul 20167:00 amRNSUpdate on pending 2015 Annual Results
29th Jun 20167:30 amRNSStatement re. Suspension
29th Jun 20167:30 amRNSSuspension - Graphene Nanochem Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.